Articles tagged with Multiple Sclerosis
The discovery of lymphatic vessels in the brain could have significant implications for understanding and treating neurological diseases such as autism, Alzheimer's, and multiple sclerosis. The findings, published in Nature, suggest that these vessels may play a major role in immune responses to neurodegenerative diseases.
Researchers found that innate lymphoid cells in males produce a protein that protects against the disease, while female mice remain inactive and do not produce this protein. This discovery opens up new avenues for investigation into sex-determined disease susceptibility.
Research suggests people with MS may have double the risk of dying early compared to those without the disease. Younger individuals with MS are particularly vulnerable, facing a three times higher risk of death.
Researchers have identified a faulty 'brake' within immune cells that drives excessive inflammation in multiple sclerosis. This discovery produces vital research tools and could lead to new therapies for the disease.
A team at CHUM Research Centre and University of Montreal has identified a molecule called MCAM that could delay the onset of multiple sclerosis. Blocking this molecule may significantly slow disease progression.
A study at Brigham and Women's Hospital discovered a genetic variant, SLC9A9, associated with patients' likelihood of responding to interferon-beta treatment. The variant may also play a role in regulating immune cells involved in inflammatory diseases like MS.
A study confirms that GM-CSF drives inflammation and neuronal damage in MS, explaining why INF-Beta is effective at reducing MS attacks. The cytokine is also identified as a potential target for new therapies.
Researchers at Gladstone Institutes discovered a way to prevent MS onset in mice by blocking SIRT1, suggesting its role in autoimmune disorders. The treatment also shows promise for other diseases like type I diabetes.
A new study reveals a sharp increase in MS drug costs over the past 20 years, with long-standing drugs like Betaseron and Copaxone seeing average annual price hikes of 21-36%. The study highlights the need for reform to address unsustainable pricing and ensure life-changing treatments remain accessible to patients.
A new study found that US multiple sclerosis drug prices have soared by 700% in two decades, with no drugs available for under $50,000 a year. The research highlights systemic problems in the pharmaceutical industry and a need for public awareness and involvement.
A Baltimore researcher has received a $260,000 award from the American Academy of Neurology to investigate the role of nitric oxide in multiple sclerosis. The goal is to examine the ability of selegiline and related drugs to alleviate disease symptoms in rodent models of MS.
Researchers at George Washington University and Case Western Reserve University have discovered two drugs that effectively treat multiple sclerosis by reversing the immune system's attack on nerve insulation, leading to increased remyelination. The study found that miconazole and clobetasol can promote myelination and enhance repair of...
Researchers discovered that netrin-1 regulates the blood-brain barrier by promoting tight junction proteins. Delivering netrin-1 to mice with MS improved symptoms, highlighting its potential therapeutic benefits.
A study led by St. Jude Children's Research Hospital scientists identified a protein called NLRP12 that helps regulate inflammation in T cells. The findings suggest how mutations in the Nlrp12 gene cause disease, paving the way for developing targeted therapies to ease symptoms of autoinflammatory diseases like multiple sclerosis and c...
A new study found that nearly 40% of multiple sclerosis patients who stopped taking their medication experienced some level of disease activity. Patients who stopped taking their medication were more likely to experience relapses and disability progression than those who continued treatment.
A study of 1,964 patients found extending natalizumab dosing up to 8 weeks is well-tolerated and effective in treating MS disease activity. No cases of progressive multifocal leukoencephalopathy were reported in the extended dosing group.
Scientists at Case Western Reserve University found that two topical medicines can activate mouse and human brain stem cells, reversing paralysis and repairing damage caused by multiple sclerosis. The approach offers a potential new way to reverse disability in MS patients.
Researchers discovered two drugs, miconazole and clobetasol, that stimulate stem cells to repair white matter and reverse paralysis in multiple sclerosis. The study found that these compounds activate oligodendrocyte progenitor cells to increase myelination, potentially leading to new treatments for the disease.
Researchers found that those taking phenytoin had 30% less damage to the nerve fiber layer and a 34% higher macula volume compared to placebo recipients. Vision recovery was successful, but long-term visual outcomes showed no significant differences between groups.
A Phase 2 study found that the experimental antibody anti-LINGO-1 significantly improved conduction in people with acute optic neuritis, a common precursor to multiple sclerosis. The treatment also led to improved recovery of myelin, a fatty substance surrounding nerves damaged in MS.
A subanalysis of the MEMREHAB trial found that deficits in processing speed negatively affect the benefits of the modified Story Memory Technique (mSMT) for individuals with MS. Processing speed may be an indicator of cognitive decline, which can impact the effectiveness of mSMT.
Researchers discovered that increasing brain activity can stimulate myelin production, which protects nerve fibers. This finding could lead to new treatments for multiple sclerosis.
A new trial will evaluate strategies to improve attention and memory for people with multiple sclerosis, aiming to boost everyday life activities. The 10-week group intervention will focus on improving attention and reducing memory problems in daily life.
Researchers have developed a new drug-like molecule called WEHI-345 that binds to and inhibits a key immune signalling protein, preventing the release of inflammatory cytokines. The molecule showed promise in preventing the progression of multiple sclerosis in 50% of cases.
A study found that guanabenz, a blood pressure medication, enhances an innate cellular protective response and prevents myelin loss in animal models of multiple sclerosis. The drug's unique mechanism provides protection against MS by reducing inflammation and preserving myelin levels.
Researchers discovered a genetic variation, STK11 SNP, significantly increasing the risk of developing multiple sclerosis in women. The study involved three sisters among five siblings with MS and found the variant to be prevalent in 7% of the general population.
Researchers found that a protein called TREM2 triggers the clearance of debris from the brain, which can contribute to neurological diseases. Triggering this protein may help slow the progression of conditions like Alzheimer's and multiple sclerosis.
Researchers have discovered a way to keep remyelination going using an FDA-approved drug solifenacin, which boosts myelin synthesis and improves auditory function in mice with myelin-related disease. The study shows that targeting human oligodendrocyte progenitor cells with solifenacin promotes differentiation and myelin production.
A new study by University of Vermont neurologist Andrew Solomon and colleagues reports that MS patients want to know the details of their physicians' financial relationships with pharmaceutical companies. The study found that disclosure of these relationships can influence patients' decisions to participate in clinical trials.
A new study suggests that drinking coffee may reduce the risk of developing multiple sclerosis (MS). Researchers analyzed data from two studies involving over 3,700 people with MS and found that those who consumed high amounts of coffee had a lower risk of developing the disease. The study supports the idea that caffeine may have prote...
Women with multiple sclerosis may have lower levels of important antioxidant and anti-inflammatory nutrients like folate from food and vitamin E compared to healthy people. The study found that women with MS had lower average intake of these nutrients and a lower percentage of calories from fat.
A new treatment shows promise in reducing muscle cramp intensity by three times, taking effect within minutes and lasting up to six hours.
A promising new approach to treat multiple sclerosis has been discovered by scientists at the Centre for Addiction and Mental Health. They identified a previously unknown change in the spinal cord related to MS and developed a peptide that disrupts this change, leading to major improvements in neurological functioning.
Researchers at Trinity College Dublin have identified a breakthrough molecule, MCC950, that suppresses the NLRP3 inflammasome, a key process in inflammatory diseases. The discovery has significant implications for treating various conditions, including arthritis, multiple sclerosis, and Muckle-Wells syndrome.
A new study found that stem cell transplants significantly reduced disease activity and brain damage in people with severe multiple sclerosis, compared to the existing drug mitoxantrone. The treatment showed promise as a potential alternative for those not responding well to standard treatments.
Kessler Foundation researchers found that subjective and objective cognitive fatigue are independent factors, with increased time on task leading to higher levels of fatigue in MS individuals. Task length was the key factor associated with cognitive fatigue, supporting the Temporal Fatigue hypothesis.
A preliminary study found that nonmyeloablative hematopoietic stem cell transplantation improved measures of disability and quality of life in relapsing-remitting multiple sclerosis patients. The treatment also showed significant improvement in physical function, cognitive function, and a reduction in brain lesions associated with MS.
A common gut microbe may protect against multiple sclerosis (MS) in women. The study found that women with MS who tested positive for Helicobacter pylori had lower disability scores than those who tested negative.
A large-scale study in Denmark and Sweden found no increased risk of multiple sclerosis among girls and women who received HPV vaccination. The study analyzed over 3.9 million individuals and 1.9 million vaccine doses, concluding that the qHPV vaccine is safe for use in this population.
After a small number of MS patients received high-dose immunosuppressive therapy and then transplanted with their own hematopoietic stem cells, most sustained remission of active relapsing-remitting MS. Improvements in neurological function, quality-of-life, and functional scores were also noted.
A study of 219 MS patients found that only 46% maintained no-evidence-of-disease-activity for clinical and MRI measures at one year, decreasing to 27.5% at two years and 7.9% after seven years.
Researchers at CWRU developed a 24-week home-based exercise program using customized pamphlets to help people with MS stay physically active. The program showed promise in improving physical function and reducing symptom severity, particularly for women with relapsing-remitting MS.
Carmela Abraham, a professor at Boston University School of Medicine, has received the Massachusetts Neuroscience Consortium Award for her research on multiple sclerosis and the life extension protein Klotho. Her work identifies Klotho as a neuroprotective protein that can benefit animal models of Alzheimer's and multiple sclerosis.
A team of researchers from the University of Surrey has identified a rogue protein in multiple sclerosis, which attacks the body's central nervous system. The discovery could lead to a better understanding of the disease and new treatments against neurodegenerative diseases.
A team of researchers has identified a chemical compound called indazole chloride that can decrease the effects of multiple sclerosis. Ind-Cl works by inhibiting selective inflammation and remyelinating axons, restoring neuronal function and potentially reducing MS progression.
Researchers found a new type of immune T helper cells called TH-GM cells play a crucial role in the immune system and pathogenesis of neuronal inflammation. Blocking IL-7 or STAT5 could provide significant therapeutic benefits for MS.
A new study by Penn and Dresden researchers has identified the protein Del-1 as a key player in blocking multiple sclerosis relapses in mice. The protein, also found to prevent inflammation and bone loss in gum disease, shows promise as a potential therapeutic target for treating neurodegenerative diseases.
A new study demonstrates that people with multiple sclerosis often have trouble recognizing emotions conveyed by facial expressions, and now shows similar difficulties with emotions expressed through body posture. The research suggests that this difficulty is unrelated to identifying one's own emotions, a disorder known as alexithymia.
Researchers developed a mathematical model to analyze data from genome-wide association studies, pinpointing genetic variants that cause autoimmune diseases. The study found strong links between the immune system and neurologic disease MS, suggesting a primary role of the immune system in causing the disease.
A new study pinpoints the complex genetic origins of multiple autoimmune diseases, including type 1 diabetes and MS. The researchers discovered that specific DNA variations, even outside genes, can alter immune system functions. Epigenetic characteristics of immune cells were also found to play a crucial role in disease development.
Researchers at EMBL found that IGF-1 enhances T-reg cell production, suppressing auto-immune diseases like type-1 diabetes and multiple sclerosis. The molecule is already approved for use in patients, paving the way for clinical trials.
The Weizmann Institute of Science has developed a novel, highly active interferon variant called YNSalpha8. PASylation technology extended its half-life in the body, resulting in improved protection from disease progression in a mouse model of human multiple sclerosis.
A recent study published in JAMA Neurology found no long-term link between vaccine administration and the development of multiple sclerosis (MS) or other central nervous system demyelinating syndromes. However, a short-term increased risk was observed in younger patients, which may be attributed to existing disease.
A large retrospective study found that nearly 60% of patients with both uveitis and multiple sclerosis (MS) are diagnosed with each condition within a five-year span. The study also revealed that MS is more likely to be diagnosed before or after uveitis, not simultaneously.
Dr. Lauren Strober will update the Symbol Digit Modalities Test (SDMT) to improve its use in clinical settings for individuals with Multiple Sclerosis (MS). The updated test will more accurately assess processing speed changes over time, enabling better prediction of disease progression and outcomes.
The Oklahoma Medical Research Foundation will receive a two-year $280,000 grant to investigate the role of BAFF and APRIL molecules in multiple sclerosis progression. This project aims to understand how inhibiting these molecules affects disease symptoms in experimental models.
Researchers found that patients with Multiple Sclerosis (MS) can safely tolerate treatment with cells cultured from human placental tissue. Early signals also suggest the potential for repairing damaged nerve tissues, offering a new frontier in treatment for the disease.
A 10-week psychoeducational wellness program improved mood, overall mental health, perceived stress, and pain in people with multiple sclerosis. The study, published in the International Journal of MS Care, suggests that individuals with MS may benefit from comprehensive wellness programs.
The International Progressive Multiple Sclerosis (MS) Alliance awarded a $30 million grant to researchers worldwide to tackle the devastating form of MS. Kessler Foundation's pilot study in rehabilitation addresses cognitive dysfunction, aiming to improve quality of life for individuals with progressive MS.
Kessler Foundation researchers have discovered a link between slowed processing speed and executive deficits in people with multiple sclerosis. The study found that slower processing speed accounted for the observed executive function deficits, suggesting a potential target for cognitive rehabilitation strategies.